Lung Stent Market By Product Type (Self-Expandable Stents, Non-Expandable Stents), By Material (Metallic Stents, Silicone Stents, Hybrid Stents), By Application (Airway Obstructions, Lung Cancer, Chronic Obstructive Pulmonary Disease [COPD]), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region; Global Insights & Forecast (2023 ? 2030)

As per Intent Market Research, the Lung Stent Market was valued at USD 3.7 Billion in 2024-e and will surpass USD 5.8 Billion by 2030; growing at a CAGR of 7.7% during 2025-2030.

The global lung stent market is witnessing robust growth, driven by increasing incidences of respiratory disorders, advancements in stent technology, and a growing aging population prone to pulmonary conditions. Lung stents, primarily utilized to treat airway obstructions, play a critical role in improving patient outcomes by restoring normal airflow. The market's growth is further fueled by rising awareness among healthcare providers and improvements in minimally invasive procedures.

Self-Expandable Stents Are Largest Owing to Versatile Applications

Self-expandable stents dominate the lung stent market due to their flexibility, adaptability, and efficacy in treating complex airway conditions. These stents are widely used in managing airway obstructions caused by lung cancer or chronic obstructive pulmonary disease (COPD). Their ability to expand naturally upon deployment provides effective and long-lasting relief for patients.

Recent advancements in self-expandable stents, such as the use of nitinol and drug-eluting coatings, further enhance their performance, making them a preferred choice among healthcare professionals. Their ease of implantation and compatibility with various airway anatomies contribute significantly to their widespread adoption.

Hybrid Stents Are Fastest Growing Owing to Enhanced Features

Hybrid stents are gaining traction as the fastest-growing segment, combining the benefits of both metallic and silicone materials. These stents address limitations of traditional stents by offering improved flexibility, biocompatibility, and structural integrity, making them ideal for complex and dynamic airway conditions.

The demand for hybrid stents is driven by their growing application in high-risk pulmonary conditions and their ability to reduce complications such as granulation tissue formation. Innovations in hybrid stent design are expected to further propel their adoption in the coming years.

Lung Cancer Application Is Largest Owing to Rising Prevalence

Lung cancer remains the largest application segment in the lung stent market, accounting for a significant share due to its high global prevalence. Lung stents are crucial in palliative care for advanced-stage lung cancer patients, providing relief from airway obstruction and enhancing quality of life.

The increasing number of lung cancer cases, coupled with advancements in diagnostic techniques, has led to early detection and the subsequent use of stents. Additionally, ongoing research into combining stent therapy with targeted cancer treatments is likely to expand their therapeutic applications.

COPD Application Is Fastest Growing Owing to Increasing Disease Burden

The chronic obstructive pulmonary disease (COPD) segment is witnessing rapid growth, fueled by rising global prevalence and the increasing adoption of stents as a supportive therapy. COPD patients often experience airway narrowing or obstruction, which can be effectively managed with stent placement.

The growing geriatric population, coupled with high smoking rates and exposure to pollutants, drives the COPD segment. Innovations in stent design to reduce infection risks and enhance patient comfort are expected to further boost adoption in this segment.

Hospitals Are Largest Owing to Comprehensive Treatment Facilities

Hospitals account for the largest share of the lung stent market, offering comprehensive care and advanced infrastructure for complex procedures. Hospitals are the primary choice for stent implantation, as they provide access to skilled pulmonologists and advanced imaging technologies.

The increasing establishment of multispecialty hospitals in emerging economies, coupled with government initiatives to improve healthcare infrastructure, has bolstered the dominance of hospitals in the lung stent market. Their role in post-operative care also strengthens their position as the leading end-user segment.

Ambulatory Surgical Centers Are Fastest Growing Owing to Convenience

Ambulatory surgical centers (ASCs) are emerging as the fastest-growing end-user segment due to their cost-effectiveness and convenience. These centers offer minimally invasive stent implantation procedures with reduced hospital stay, making them a preferred choice among patients and physicians.

The shift toward outpatient care, coupled with advancements in portable medical equipment and stent delivery systems, has accelerated the adoption of ASCs in the lung stent market. Their rapid growth is further supported by favorable reimbursement policies in developed economies.

North America Is Largest Owing to Advanced Healthcare Infrastructure

North America dominates the lung stent market, driven by advanced healthcare infrastructure, high adoption of innovative medical technologies, and a well-established reimbursement framework. The region's high prevalence of lung cancer and COPD further supports market growth.

The United States, being the largest contributor, benefits from strong research and development activities, leading to the introduction of advanced lung stents. The presence of major market players and a growing focus on minimally invasive procedures enhance the region's leadership.

Competitive Landscape

The lung stent market is characterized by intense competition among leading companies such as Boston Scientific Corporation, Cook Medical, and Merit Medical Systems. These players focus on strategic collaborations, product innovations, and regional expansions to strengthen their market position.

The competitive landscape is also shaped by the entry of emerging players offering cost-effective solutions. Continuous research and development, coupled with regulatory approvals, are expected to foster innovation and drive market growth in the coming years.

The competitive landscape is also shaped by the entry of emerging players offering cost-effective solutions. Continuous research and development, coupled with regulatory approvals, are expected to foster innovation and drive market growth in the coming years.

Recent Developments:

• Medtronic received FDA approval for its latest bronchial stent, providing enhanced airway support for patients with advanced lung cancer.
• Cook Medical has partnered with various research institutes to develop innovative hybrid stents, focusing on improving the safety and efficacy of lung stent implants.
• Teleflex has acquired EndoMed Systems, a move aimed at expanding its product line and strengthening its position in the lung stent market.
• Olympus Corporation has launched a new airway stent system, offering improved flexibility and ease of use in treating patients with obstructed airways due to COPD and lung cancer.

List of Leading Companies:

• Boston Scientific Corporation
• Cook Medical
• Merit Medical Systems, Inc.
• Micro-Tech (Nanjing) Co., Ltd.
• Taewoong Medical Co., Ltd.
• Novatech SA
• EFER Endoscopy
• Olympus Corporation
• Terumo Corporation
• Endo-Flex GmbH
• Stening SRL
• Hood Laboratories
• Medtronic PLC
• BIOTEQUE Corporation
• Allium Medical

Report Scope: